Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma

NCT03687099 | Completed

• 1 other identifier: PI2018_843_0011
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Despite advances in neurosurgery , radiotherapy and chemotherapy, the median survival in GBM patients is only 15 months from diagnosis. Immunotherapy by checkpoint inhibitors (PD1 /PDL-1) appears as a promising treatment for many cancers. However, first clinical results are disappointing for GBM. An hypothesis is the immunosuppressive activity from infiltrating non-tumor cells. Conversion of non-tumor cells from an immunosuppressive to an immuno-activating phenotype could be attempted in a therapeutic perspective.

Conditions

Glioblastoma

Keywords

Glioblastoma; CD45; Lymphocytes; Microglia; Macrophage

Outcome Measures

Primary Outcomes (1)

• number of cells which express CD45 in the immunological environment from GBM.

  number of cells which express CD45 in the immunological environment from GBM, with using NanoString/RNAseq (NGS) and immunohistology

  1

Interventions

no intervention OTHER

Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Histological samples of GBM

You may qualify if:

• Formalin-fixed paraffin-embedded GBM samples from tumor bank of the pathological laboratory of the University Hospital of Amiens-Picardie.
• Histologic diagnosis of a glioblastoma according to the WHO classification of central nervous system
• Radical surgical removal in order to have enough histological material and to homogenize the main prognostic factor that is the surgical removal.
• Patients with more than 18 years old.
• Patients informed who have signed a consent form for using the tumor for research purposes without personal benefit. If patients were died, absence of objection known for the anonymous use of the tumor for scientific purpose.
• Be insured under one social security system.
• Committee for the protection of persons approval.

You may not qualify if:

• Relapsed GBM
• Other brain tumors.
• Medical, psychological or social conditions not allowing the comprehension of the conduct of the study for patients able to give their opinion.
• Patient under curatorship.

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead

Study Sites (1)

CHU Amiens-Picardie

Amiens, 80054, France

Location

MeSH Terms

Conditions

Glioblastoma

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 17, 2018
• First Posted: September 27, 2018
• Study Start: April 30, 2018
• Primary Completion: November 8, 2019
• Study Completion: November 8, 2019
• Last Updated: July 16, 2020

Record last verified: 2020-07

Locations

FR (1)